The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Hikma gets preliminary approval from US FTC for Custopharm deal

Wed, 20th Apr 2022 07:39

(Sharecast News) - Hikma Pharmaceuticals has received preliminary approval from the US Federal Trade Commission for the acquisition of sterile injectables company Custopharm Inc from Water Street Healthcare for up to $425m.

The group said on Wednesday that it will now work towards closing the acquisition. It noted that the parties have obtained all regulatory approvals required to close the deal.

Hikma announced in September last year that it had agreed to buy Custopharm. It said the acquisition complements its injectable product portfolio and pipeline, adding 13 approved products and additional pipeline products

It also enhances the group's R&D capabilities, "adding an experienced scientific team of dedicated R&D professionals with a proven ability to develop and commercialise complex sterile injectable products and a state-of-the-art R&D laboratory in California," it said at the time.

Related Shares

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

26 Apr 2024 13:36

UK dividends calendar - next 7 days

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 10:15

Hikma Pharmaceuticals backs outlook after making strong start to 2024

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.

25 Apr 2024 08:01

Hikma delivers strong Q1, holds on to guidance

(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.